摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one | 1204484-58-1

中文名称
——
中文别名
——
英文名称
(1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one
英文别名
(1R,5S,6S)-5-[tert-butyl(dimethyl)silyl]oxy-7-oxa-3-azabicyclo[4.1.0]heptan-2-one
(1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one化学式
CAS
1204484-58-1
化学式
C11H21NO3Si
mdl
——
分子量
243.378
InChiKey
ISGVBZVIARRSCC-DJLDLDEBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.27
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    50.9
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 、 sodium cyanamide 在 盐酸 作用下, 以 二甲基亚砜 为溶剂, 反应 48.0h, 以40%的产率得到N-((3S,4S,5S)-5-((tert-butyldimethylsilyl)oxy)-4-hydroxy-2-oxopiperidin-3-yl)cyanamide
    参考文献:
    名称:
    新型杂环2-Oxa-4,7-二氮杂双环[3.3.1]Non-3-Ene的合成及晶体结构
    摘要:
    化合物 5 含有新型杂环 2-oxa-4,7-二氮杂双环 [3.3.1]non-3-ene,已通过合成方法获得具有天然产物样复杂性的恶唑和 1,3-二氮杂环。 δ-内酰胺氰胺的环化和重排。当将此程序应用于甲硅烷基保护的 N-((3S,4S,5S)-4,5-dihydroxy-2-oxopiperidin-3-yl) 氰胺 (2b) 时,观察到新型杂双环支架 5 的形成预期的恶唑 (3b) 和二氮杂 (4b) 产物。描述了 5 和二氮杂环庚烷 4b 的晶体结构。化合物 5 在单斜晶系中从甲醇结晶,P21 空间群,晶胞参数 a = 15.3402(9), b = 7.2717(4), c = 22.5803(13), β = 106.8620(10),晶胞体积为 2410.5 (2) A3.Graphical Abstract 描述了标题化合物的合成和晶体结构。
    DOI:
    10.1007/s10870-011-0212-6
  • 作为产物:
    描述:
    (1R,6R)-5-hydroxy-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 、 叔丁基二甲基氯硅烷咪唑 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.08h, 以56%的产率得到(1R,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one
    参考文献:
    名称:
    来自氰胺诱导的环氧-δ-内酰胺重排的具有天然产物样复杂性的 1,3-二氮杂
    摘要:
    开发了一种合成程序,用于构建 RNA 导向的配体库,以构建具有天然产物样复杂性的 1,3-二氮杂环支架。设计了一种分子构建块,它结合了 RNA 结合天然产物的特征,包括围绕刚性非平面支架的高密度氢键供体和受体,具有直接的全合成可及性,允许对化学空间进行广泛的控制。1,3-二氮杂环支架的合成是通过前所未有的氰胺诱导的环氧-δ-内酰胺重排实现的。
    DOI:
    10.1021/ol9026914
点击查看最新优质反应信息

文献信息

  • 1,3-Diazepanes of Natural Product-Like Complexity from Cyanamide-Induced Rearrangement of Epoxy-δ-lactams
    作者:Sanjay Dutta、Cody J. Higginson、Bao T. Ho、Kevin D. Rynearson、Sergey M. Dibrov、Thomas Hermann
    DOI:10.1021/ol9026914
    日期:2010.1.15
    A synthetic procedure toward 1,3-diazepane scaffolds of natural product-like complexity was developed for the construction of RNA-directed ligand libraries. A molecular building block was designed that combines the characteristics of RNA-binding natural products, including a high density of hydrogen bond donors and acceptors around a rigid, nonplanar scaffold with straightforward total-synthetic accessibility
    开发了一种合成程序,用于构建 RNA 导向的配体库,以构建具有天然产物样复杂性的 1,3-二氮杂环支架。设计了一种分子构建块,它结合了 RNA 结合天然产物的特征,包括围绕刚性非平面支架的高密度氢键供体和受体,具有直接的全合成可及性,允许对化学空间进行广泛的控制。1,3-二氮杂环支架的合成是通过前所未有的氰胺诱导的环氧-δ-内酰胺重排实现的。
  • Synthesis and Crystal Structure of a Novel Heterocycle, 2-Oxa-4,7-Diazabicyclo[3.3.1]Non-3-Ene
    作者:Sanjay Dutta、Sergey M. Dibrov、Bao T. Ho、Cody J. Higginson、Thomas Hermann
    DOI:10.1007/s10870-011-0212-6
    日期:2012.2
    oxazole (3b) and diazepane (4b) products. The crystal structures of 5 and diazepane 4b are described. Compound 5 crystallized from methanol in the monoclinic system, P21 space group with unit cell parameters a = 15.3402(9), b = 7.2717(4), c = 22.5803(13), β = 106.8620(10) and a cell volume of 2410.5(2) A3.Graphical AbstractThe synthesis and crystal structure of the title compound is described.
    化合物 5 含有新型杂环 2-oxa-4,7-二氮杂双环 [3.3.1]non-3-ene,已通过合成方法获得具有天然产物样复杂性的恶唑和 1,3-二氮杂环。 δ-内酰胺氰胺的环化和重排。当将此程序应用于甲硅烷基保护的 N-((3S,4S,5S)-4,5-dihydroxy-2-oxopiperidin-3-yl) 氰胺 (2b) 时,观察到新型杂双环支架 5 的形成预期的恶唑 (3b) 和二氮杂 (4b) 产物。描述了 5 和二氮杂环庚烷 4b 的晶体结构。化合物 5 在单斜晶系中从甲醇结晶,P21 空间群,晶胞参数 a = 15.3402(9), b = 7.2717(4), c = 22.5803(13), β = 106.8620(10),晶胞体积为 2410.5 (2) A3.Graphical Abstract 描述了标题化合物的合成和晶体结构。
查看更多

同类化合物

7-亚乙基-环戊二烯并(b)环氧乙烷并(c)吡啶六氢衍生物. 4-甲基-3-氧杂-6-氮杂三环[3.2.0.02,4]庚烷-7-酮 3-氧杂-6-氮杂三环[3.2.2.02,4]壬烷(8CI,9CI) 3-氧杂-1-氮杂三环[5.2.0.02,4]壬烷 2-氧杂-6-氮杂三环[4.3.1.01,3]癸烷 (1S,2R,4S,5R)-3-氧杂-6-氮杂三环[3.2.1.02,4]辛烷-7-酮 (5R,7S,8R,8aR)-5-dodecyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one (2S,2R,4S,5R,6S)-(+)-2-{2-[2-[1,3]-dioxolan-2-yl-ethyl]-6-methyl-4,5-epoxy-3,6-dihydro-2H-pyridin-1-yl}-2-phenylethanol (5R,7R,8S,8aR)-5-ethyl-7,8-epoxyoxazolidino[3,4-a]piperidine-3-one dihydroabikoviromycin (1R,6R)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-1-(hydroxymethyl)-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1aR,6aS,7R,7aS)-7-(t-butyldimethylsilyloxy)tetrahydro-1aH-oxazolo[3,4-a]oxireno[2,3-d]pyridin-4(2H)-one 11-formyl-(1rN,2tH,4tH,6cN,7tH,9tH)-3,8-dioxa-11-aza-tetracyclo[4.4.1.02,4.07,9]undecane 7-Oxa-2-azabicyclo[4.1.0]heptane (1S,6S)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-1-(hydroxymethyl)-3-[(1R)-2-hydroxy-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6S)-3-[(1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-phenylethyl]-1-(hydroxymethyl)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-Oxa-10-azatricyclo[4.3.1.0~2,4~]decane (3S,5R,6R,7R)-6-hydroxy-4,9-dioxa-1-azatricyclo[5.3.0.03,5]decan-10-one (1RS,2SR,4RS,5SR)-3-oxa-6-azatricyclo[3.2.1.02,4]octan-7-one (1S,6S)-1-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-[(1S)-1-phenylethyl]-7-oxa-3-azabicyclo[4.1.0]heptan-2-one 3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane 3α,4α-epoxy-2-piperidone (+)-tedanalactam 5-amino-1,2-anhydro-5-deoxy-D-lyxono-1,4-lactame (1R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,5R,6S)-5-((tert-butyldimethylsilyl)oxy)-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1S,6R)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6S)-4,4,6-trimethyl-7-oxa-3-azabicyclo[4.1.0]heptan-2-one (1R,6R)-3-(cyclopropylmethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-ethyl-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methylpropyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-(2-methoxyethyl)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6R)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,6S)-7-oxa-3-azabicyclo[4.1.0]heptane (1R,6S)-7-oxa-2-azabicyclo[4.1.0]heptane (1S,6R)-7-oxa-2-azabicyclo[4.1.0]heptane (1R,6R)-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2S,4R,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2R,4S,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1S,2S,4S,5R)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-4-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (2S,4R,7S)-3-oxa-1-azatricyclo[5.2.0.02,4]nonane (1R,6R)-1-methyl-3-propyl-7-oxa-3-azabicyclo[4.1.0]heptane (1S,2R,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1S,2S,4S,5S)-2-methyl-3-oxa-6-azatricyclo[3.2.0.02,4]heptan-7-one (1R,6S)-3-methyl-7-oxa-3-azabicyclo[4.1.0]heptane